Novo Nordisk Completes $9.02177 Billion Share Repurchase

Novo Nordisk A/S, the Danish healthcare company, announced a significant share repurchase program on May 6, 2026. The program aims to repurchase B shares worth up to DKK 11.2 billion, with the repurchase period set to run until February 1, 2027. This initiative is part of the company's larger share repurchase plan, which is expected to total DKK 15 billion over a 12-month period starting February 4, 2026.

Since the program's inception, Novo Nordisk has made substantial progress, having repurchased 32,034,179 B shares as of September 4, 2026. The average share price for these transactions was DKK 281.63, amounting to a total transaction value of DKK 9.02177 billion. With these repurchases, Novo Nordisk now holds 46,074,876 B shares as treasury shares, representing 1.0% of the share capital. The total number of A and B shares in the company, including treasury shares, stands at 4,465,000,000.

Novo Nordisk, founded in 1923 and headquartered in Bagsværd, Denmark, is a global leader in healthcare. The company’s purpose is to drive change to defeat serious chronic diseases, leveraging its heritage in diabetes to pioneer scientific breakthroughs, expand access to medicines, and ultimately work towards preventing and curing diseases. With a workforce of approximately 68,800 people spread across 80 countries, Novo Nordisk markets its products in around 170 countries. Its B shares are listed on Nasdaq Copenhagen (Novo-B), and ADRs are listed on the New York Stock Exchange (NVO).

As of September 4, 2026, Novo Nordisk has completed a significant portion of its initial share repurchase program. The company anticipates that the repurchase will continue until February 1, 2027, with the overall aim of reducing the company’s share capital and potentially increasing the value of the remaining shares. The transactions are detailed on the company’s website, ensuring transparency and accountability in its financial operations.